0000950170-25-013752.txt : 20250204 0000950170-25-013752.hdr.sgml : 20250204 20250204173006 ACCESSION NUMBER: 0000950170-25-013752 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250203 FILED AS OF DATE: 20250204 DATE AS OF CHANGE: 20250204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bredt David CENTRAL INDEX KEY: 0002022087 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42121 FILM NUMBER: 25589747 MAIL ADDRESS: STREET 1: C/O RAPPORT THERAPEUTICS STREET 2: 1325 BOYLSTON ST., SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rapport Therapeutics, Inc. CENTRAL INDEX KEY: 0002012593 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880724208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: 857-321-8020 MAIL ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 4 1 ownership.xml 4 X0508 4 2025-02-03 0002012593 Rapport Therapeutics, Inc. RAPP 0002022087 Bredt David RAPPORT THERAPEUTICS, INC. 1325 BOYLSTON STREET, SUITE 401 BOSTON MA 02215 false true false false Chief Scientific Officer false Stock Option (Right to Buy) 16.6 2025-02-03 4 A false 100000 0 A 2035-02-03 Common Stock 100000 100000 D The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date. /s/ Troy Ignelzi, Attorney-in-Fact 2025-02-04